{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:07:37Z","timestamp":1762884457969,"version":"3.45.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004097","name":"Fondation ARC pour la Recherche sur le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,11,30]]},"DOI":"10.1038\/s41416-025-03183-2","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:33:32Z","timestamp":1757550812000},"page":"1554-1564","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis"],"prefix":"10.1038","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6977-4213","authenticated-orcid":false,"given":"Abderaouf","family":"Hamza","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3893-9879","authenticated-orcid":false,"given":"Pierre","family":"Gestraud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alicia","family":"Tran-Dien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laur\u00e8ne","family":"Syx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0042-6023","authenticated-orcid":false,"given":"Sophie","family":"Vacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quentin","family":"Peretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2535-1010","authenticated-orcid":false,"given":"Ludovic","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valery","family":"Attignon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Soubeyran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"J\u00e9z\u00e9quel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Planchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samia","family":"Melaabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trenton","family":"Dailey-Chwalib\u00f3g","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4233-8478","authenticated-orcid":false,"given":"Marta","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6963-2968","authenticated-orcid":false,"given":"Stefan","family":"Michiels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Servant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9772-4686","authenticated-orcid":false,"given":"Christophe","family":"Le Tourneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5795-8357","authenticated-orcid":false,"given":"Fabrice","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5090-8189","authenticated-orcid":false,"given":"Benjamin","family":"Besse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maud","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2430-5429","authenticated-orcid":false,"given":"Ivan","family":"Bi\u00e8che","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"3183_CR1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.3564","volume":"48","author":"JD Campbell","year":"2016","unstructured":"Cancer Genome Atlas Research Network, Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016;48:607\u201316.","journal-title":"Nat Genet"},{"key":"3183_CR2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"The Cancer Genome Atlas Research Network.","year":"2014","unstructured":"The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543\u201350.","journal-title":"Nature"},{"key":"3183_CR3","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","volume":"19","author":"F Skoulidis","year":"2019","unstructured":"Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19:495\u2013509.","journal-title":"Nat Rev Cancer"},{"key":"3183_CR4","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Non-Small Cell Lung Cancer [Internet]. 2022. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf"},{"key":"3183_CR5","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41586-019-1056-z","volume":"569","author":"F Bertucci","year":"2019","unstructured":"Bertucci F, Ng CKY, Patsouris A, Droin N, Piscuoglio S, Carbuccia N, et al. Genomic characterization of metastatic breast cancers. Nature. 2019;569:560\u20134.","journal-title":"Nature"},{"key":"3183_CR6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cell.2022.01.003","volume":"185","author":"B Nguyen","year":"2022","unstructured":"Nguyen B, Fong C, Luthra A, Smith SA, DiNatale RG, Nandakumar S, et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell. 2022185:563\u2013575.e11.","journal-title":"Cell"},{"key":"3183_CR7","unstructured":"International Agency for Research on Cancer. Cancer Incidence, Mortality and Prevalence Worldwide [Internet]. Available from: https:\/\/gco.iarc.fr"},{"key":"3183_CR8","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/1078-0432.CCR-22-0371","volume":"28","author":"F Barlesi","year":"2022","unstructured":"Barlesi F, Tomasini P, Karimi M, Michiels S, Raimbourg J, Daniel C, et al. Comprehensive genome profiling in patients with metastatic non\u2013small cell lung cancer: the precision medicine phase II randomized SAFIR02-lung trial. Clin Cancer Res. 2022;28:OF1\u20139.","journal-title":"Clin Cancer Res"},{"key":"3183_CR9","unstructured":"The Cancer Genome Atlas, National Health Institute. https:\/\/portal.gdc.cancer.gov\/projects\/TCGA-LUAD. Genomic Data Common, TCGA-LUAD project."},{"key":"3183_CR10","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1038\/s41591-022-02047-z","volume":"28","author":"J Jee","year":"2022","unstructured":"Jee J, Lebow ES, Yeh R, Das JP, Namakydoust A, Paik PK, et al. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer. Nat Med. 2022;28:2353\u201363.","journal-title":"Nat Med"},{"key":"3183_CR11","doi-asserted-by":"crossref","unstructured":"The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, Andr\u00e9 F, Arnedos M, Baras AS, Baselga J, et al. AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discovery. 2017;7:818\u201331.","DOI":"10.1158\/2159-8290.CD-17-0151"},{"key":"3183_CR12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"3183_CR13","first-page":"pl1","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.","journal-title":"Sci Signal"},{"key":"3183_CR14","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jnci\/dji237","volume":"97","author":"LM McShane","year":"2005","unstructured":"McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). JNCI J Natl Cancer Inst. 2005;97:1180\u20134.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"3183_CR15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa031644","volume":"350","author":"The International Adjuvant Lung Cancer Trial Collaborative Group.","year":"2004","unstructured":"The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non\u2013small-cell lung cancer. N Engl J Med. 2004;350:351\u201360.","journal-title":"N Engl J Med"},{"key":"3183_CR16","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1200\/JCO.2012.48.1390","volume":"31","author":"FA Shepherd","year":"2013","unstructured":"Shepherd FA, Domerg C, Hainaut P, J\u00e4nne PA, Pignon JP, Graziano S, et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non\u2013small-cell lung cancer in four trials of adjuvant chemotherapy. JCO. 2013;31:2173\u201381.","journal-title":"JCO"},{"key":"3183_CR17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.21037\/tlcr.2018.05.01","volume":"7","author":"on behalf of the LACE-Bio Consortiu","year":"2018","unstructured":"on behalf of the LACE-Bio Consortium, Rotolo F, Zhu CQ, Brambilla E, Graziano SL, Olaussen K, et al. Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer. Transl Lung Cancer Res. 2018;7:416\u201327.","journal-title":"Transl Lung Cancer Res"},{"key":"3183_CR18","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The ensembl variant effect predictor. Genome Biol. 2016;17:122.","journal-title":"Genome Biol"},{"key":"3183_CR19","unstructured":"oncokb-annotator [Internet]. Available from: https:\/\/github.com\/oncokb\/oncokb-annotator#readme"},{"key":"3183_CR20","doi-asserted-by":"crossref","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","volume":"52","author":"Z Sondka","year":"2024","unstructured":"Sondka Z, Dhir NB, Carvalho-Silva D, Jupe S, Madhumita, McLaren K, et al. COSMIC: a curated database of somatic variants and clinical data for cancer. Nucleic Acids Res. 2024;52:D1210\u20137.","journal-title":"Nucleic Acids Res"},{"key":"3183_CR21","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/2159-8290.CD-17-0321","volume":"8","author":"MT Chang","year":"2018","unstructured":"Chang MT, Bhattarai TS, Schram AM, Bielski CM, Donoghue MTA, Jonsson P, et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Discov. 2018;8:174\u201383.","journal-title":"Cancer Discov"},{"key":"3183_CR22","unstructured":"Chakravarty D, Gao J, Phillips S, Kundra R, Zhang H, Wang J, et al. OncoKB: a precision oncology knowledge base. JCO Precision Oncol. 2017:1\u201316."},{"key":"3183_CR23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer. J Mol Diagnostics. 2017;19:4\u201323.","journal-title":"J Mol Diagnostics"},{"key":"3183_CR24","unstructured":"R Core Team. R: A language and environment for statistical computing [Internet]. Vienna, Austria; 2020. Available from: https:\/\/www.R-project.org\/"},{"key":"3183_CR25","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41586-020-2698-6","volume":"587","author":"TBK Watkins","year":"2020","unstructured":"Watkins TBK, Lim EL, Petkovic M, Elizalde S, Birkbak NJ, Wilson GA, et al. Pervasive chromosomal instability and karyotype order in tumour evolution. Nature. 2020;587:126\u201332.","journal-title":"Nature"},{"key":"3183_CR26","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","volume":"18","author":"H Hamidi","year":"2018","unstructured":"Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer. 2018;18:533\u201348.","journal-title":"Nat Rev Cancer"},{"key":"3183_CR27","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1038\/onc.2013.381","volume":"33","author":"L Du","year":"2014","unstructured":"Du L, Zhao Z, Ma X, Hsiao TH, Chen Y, Young E, et al. miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer. Oncogene. 2014;33:4307\u201315.","journal-title":"Oncogene"},{"key":"3183_CR28","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1073\/pnas.1701690114","volume":"114","author":"P Shahi","year":"2017","unstructured":"Shahi P, Wang CY, Lawson DA, Slorach EM, Lu A, Yu Y, et al. ZNF503\/Zpo2 drives aggressive breast cancer progression by down-regulation of GATA3 expression. Proc Natl Acad Sci USA. 2017;114:3169\u201374.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3183_CR29","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/s41586-022-04809-8","volume":"606","author":"SA Patel","year":"2022","unstructured":"Patel SA, Hirosue S, Rodrigues P, Vojtasova E, Richardson EK, Ge J, et al. The renal lineage factor PAX8 controls oncogenic signalling in kidney cancer. Nature. 2022;606:999\u20131006.","journal-title":"Nature"},{"key":"3183_CR30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.matbio.2015.01.022","volume":"44\u201346","author":"K Kessenbrock","year":"2015","unstructured":"Kessenbrock K, Wang CY, Werb Z. Matrix metalloproteinases in stem cell regulation and cancer. Matrix Biol. 2015;44\u201346:184\u201390.","journal-title":"Matrix Biol"},{"key":"3183_CR31","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41588-020-0592-7","volume":"52","author":"DJH Shih","year":"2020","unstructured":"Shih DJH, Nayyar N, Bihun I, Dagogo-Jack I, Gill CM, Aquilanti E, et al. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet. 2020;52:371\u20137.","journal-title":"Nat Genet"},{"key":"3183_CR32","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1038\/bcj.2014.18","volume":"4","author":"X Sun","year":"2014","unstructured":"Sun X, Lu B, Hu B, Xiao W, Li W, Huang Z. Novel function of the chromosome 7 open reading frame 41 gene to promote leukemic megakaryocyte differentiation by modulating TPA-induced signaling. Blood Cancer J. 2014;4:e198.","journal-title":"Blood Cancer J"},{"key":"3183_CR33","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1042\/BCJ20200879","volume":"478","author":"FJ Yan","year":"2021","unstructured":"Yan FJ, Wang YJ, Wang SE, Hong HT. PKC\u03b1\/ERK\/C7ORF41 axis regulates epidermal keratinocyte differentiation through the IKK\u03b1 nuclear translocation. Biochem J. 2021;478:839\u201354.","journal-title":"Biochem J"},{"key":"3183_CR34","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s00432-019-03032-9","volume":"145","author":"L Liu","year":"2019","unstructured":"Liu L, Song X, Li X, Xue L, Ding S, Niu L, et al. A three-platelet mRNA set: MAX, MTURN and HLA-B as biomarker for lung cancer. J Cancer Res Clin Oncol. 2019;145:2713\u201323.","journal-title":"J Cancer Res Clin Oncol"},{"key":"3183_CR35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbcan.2011.05.003","volume":"1816","author":"B Busser","year":"2011","unstructured":"Busser B, Sancey L, Brambilla E, Coll JL, Hurbin A. The multiple roles of amphiregulin in human cancer. Biochim et Biophys Acta (BBA) Rev Cancer 2011;1816:119\u201331.","journal-title":"Biochim et Biophys Acta (BBA) Rev Cancer"},{"key":"3183_CR36","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1158\/1078-0432.CCR-23-0859","volume":"29","author":"CJM Williams","year":"2023","unstructured":"Williams CJM, Elliott F, Sapanara N, Aghaei F, Zhang L, Muranyi A, et al. Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer. Clin Cancer Res. 2023;29:4153\u201365.","journal-title":"Clin Cancer Res"},{"key":"3183_CR37","volume":"12","author":"S Asano","year":"2022","unstructured":"Asano S, Yamasaka M, Ozasa K, Sakamoto K, Hayata-Takano A, Nakazawa T, et al. Vasoactive intestinal peptide\u2013VIPR2 signaling regulates tumor cell migration. Front Oncol. 2022;12:852358.","journal-title":"Front Oncol"},{"key":"3183_CR38","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1093\/jnci\/djs297","volume":"104","author":"G Zhuang","year":"2012","unstructured":"Zhuang G, Song W, Amato K, Hwang Y, Lee K, Boothby M, et al. Effects of cancer-associated EPHA3 mutations on lung cancer. JNCI: J Natl Cancer Inst. 2012;104:1183\u201398.","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"3183_CR39","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-023-02682-0","volume":"30","author":"A Sosinsky","year":"2024","unstructured":"Sosinsky A, Ambrose J, Cross W, Turnbull C, Henderson S, Jones L, et al. Insights for precision oncology from the integration of genomic and clinical data of 13,880 tumors from the 100,000 Genomes Cancer Programme. Nat Med. 2024;30:279\u201389.","journal-title":"Nat Med"},{"key":"3183_CR40","volume":"15","author":"R Liu","year":"2024","unstructured":"Liu R, Rizzo S, Wang L, Chaudhary N, Maund S, Garmhausen MR, et al. Characterizing mutation-treatment effects using clinico-genomics data of 78,287 patients with 20 types of cancers. Nat Commun. 2024;15:10884.","journal-title":"Nat Commun"},{"key":"3183_CR41","doi-asserted-by":"crossref","unstructured":"Lou-Qian Z, Rong Y, Ming L, Xin Y, Feng J, Lin X The Prognostic Value of Epigenetic Silencing of p16 Gene in NSCLC Patients: A Systematic Review and Meta-Analysis. Pratap J, editor. PLoS ONE. 2013;8:e54970.","DOI":"10.1371\/journal.pone.0054970"},{"key":"3183_CR42","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.canlet.2016.10.013","volume":"384","author":"CC Yu","year":"2017","unstructured":"Yu CC, Qiu W, Juang CS, Mansukhani MM, Halmos B, Su GH. Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications. Cancer Lett. 2017;384:86\u201393.","journal-title":"Cancer Lett"},{"key":"3183_CR43","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cell.2017.01.020","volume":"168","author":"MR Burgess","year":"2017","unstructured":"Burgess MR, Hwang E, Mroue R, Bielski CM, Wandler AM, Huang BJ, et al. KRAS allelic imbalance enhances fitness and modulates MAP kinase dependence in cancer. Cell. 2017;168:817\u2013829.e15.","journal-title":"Cell"},{"key":"3183_CR44","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature16967","volume":"531","author":"EM Kerr","year":"2016","unstructured":"Kerr EM, Gaude E, Turrell FK, Frezza C, Martins CP. Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities. Nature. 2016;531:110\u20133.","journal-title":"Nature"},{"key":"3183_CR45","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","volume":"52","author":"M Chan-Seng-Yue","year":"2020","unstructured":"Chan-Seng-Yue M, Kim JC, Wilson GW, Ng K, Figueroa EF, O\u2019Kane GM, et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nat Genet. 2020;52:231\u201340.","journal-title":"Nat Genet"},{"key":"3183_CR46","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nature25459","volume":"554","author":"S Mueller","year":"2018","unstructured":"Mueller S, Engleitner T, Maresch R, Zukowska M, Lange S, Kaltenbacher T, et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature. 2018;554:62\u20138.","journal-title":"Nature"},{"key":"3183_CR47","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","volume":"384","author":"MM Awad","year":"2021","unstructured":"Awad MM, Liu S, Rybkin II, Arbour KC, Dilly J, Zhu VW, et al. Acquired resistance to KRAS G12C inhibition in cancer. N Engl J Med. 2021;384:2382\u201393.","journal-title":"N Engl J Med"},{"key":"3183_CR48","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","volume":"5","author":"F Skoulidis","year":"2015","unstructured":"Skoulidis F, Byers LA, Diao L, Papadimitrakopoulou VA, Tong P, Izzo J, et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 2015;5:860\u201377.","journal-title":"Cancer Discov"},{"key":"3183_CR49","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/JTO.0b013e31820594f0","volume":"6","author":"H Sasaki","year":"2011","unstructured":"Sasaki H, Hikosaka Y, Kawano O, Moriyama S, Yano M, Fujii Y. Evaluation of Kras gene mutation and copy number gain in non-small cell lung cancer. J Thorac Oncol. 2011;6:15\u201320.","journal-title":"J Thorac Oncol"},{"key":"3183_CR50","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1038\/modpathol.2011.109","volume":"24","author":"SI Chiosea","year":"2011","unstructured":"Chiosea SI, Sherer CK, Jelic T, Dacic S. KRAS mutant allele-specific imbalance in lung adenocarcinoma. Mod Pathol. 2011;24:1571\u20137.","journal-title":"Mod Pathol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03183-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03183-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03183-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:04:52Z","timestamp":1762884292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03183-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,11,30]]}},"alternative-id":["3183"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03183-2","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"type":"print","value":"0007-0920"},{"type":"electronic","value":"1532-1827"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"F Barlesi reports personal fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Eli Lilly Oncology, F Hoffmann-La Roche Ltd, Novartis, Merck, Mirati, MSD, Pierre Fabre, Pfizer, Seattle Genetics and Takeda; grants from Abbvie, ACEA, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Eisai, Eli Lilly Oncology, F Hoffmann-La Roche Ltd., Genentech, Ipsen, Ignyta, Innate Pharma, Loxo, Novartis, Medimmune, Merck, MSD, Pierre Fabre, Pfizer, Sanofi-Aventis, and Takeda; and nonfinancial support from AstraZeneca, BMS, Merck, Pierre Fabre, and F Hoffmann-La Roche outside the submitted work. S. Michiels reports personal fees from Amaris, Roche, Sensorion, Biophytis, Servier, and Yuhan outside the submitted work. A Madroszyk reports personal fees and nonfinancial support from AstraZeneca and Roche, and nonfinancial support from Lilly outside the submitted work. I Soubeyran reports grants and nonfinancial support from AstraZeneca; grants from Takeda and ThermoFisher; and personal fees from GSK, Lilly, and Servier outside the submitted work. M. Jimenez reports grants and nonfinancial support from AstraZeneca and grants from Fondation ARC during the conduct of the study. B. Besse reports grants from 4D Pharma, AbbVie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Celgene, Cergentis, Chugai pharmaceutical, Cristal Therapeutics, Daiichi-Sankyo, Eli Lilly, EISAI, Genzyme Corporation, GSK, Inivata, IPSEN, Janssen, Onxeo, OSE immunotherapeutics, Pfizer, Roche-Genentech, Sanofi, Takeda, Tolero Pharmaceuticals, and Turning Point Therapeutics during the conduct of the study. No disclosures were reported by the other authors.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}